Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wedbush

Keros Therapeutics (NASDAQ:KROS) was downgraded by equities researchers at Wedbush from an “outperform” rating to a “neutral” rating in a report issued on Friday, MarketBeat.com reports. They currently have a $15.00 price target on the stock. Wedbush’s target price points to a potential upside of 38.76% from the stock’s previous close.

A number of other research firms have also recently weighed in on KROS. Guggenheim reaffirmed a “neutral” rating on shares of Keros Therapeutics in a research report on Friday. Scotiabank reduced their price objective on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research note on Thursday. HC Wainwright lowered their target price on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $62.56.

Keros Therapeutics Trading Up 2.8 %

Keros Therapeutics stock traded up $0.29 during mid-day trading on Friday, hitting $10.81. The company had a trading volume of 1,560,779 shares, compared to its average volume of 2,448,567. The company has a market capitalization of $437.91 million, a PE ratio of -2.07 and a beta of 1.43. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00. The stock’s 50 day moving average price is $37.51 and its two-hundred day moving average price is $47.36.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $0.39 million for the quarter. During the same period in the previous year, the company posted ($1.33) EPS. The company’s revenue was up 4750.0% on a year-over-year basis. Equities research analysts anticipate that Keros Therapeutics will post -4.74 EPS for the current year.

Institutional Investors Weigh In On Keros Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Rhumbline Advisers increased its holdings in shares of Keros Therapeutics by 20.6% in the 2nd quarter. Rhumbline Advisers now owns 41,638 shares of the company’s stock worth $1,903,000 after buying an additional 7,111 shares during the last quarter. American Century Companies Inc. raised its position in Keros Therapeutics by 24.9% during the second quarter. American Century Companies Inc. now owns 298,170 shares of the company’s stock valued at $13,626,000 after purchasing an additional 59,364 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Keros Therapeutics in the 2nd quarter worth approximately $654,000. XTX Topco Ltd purchased a new position in shares of Keros Therapeutics in the 2nd quarter worth approximately $228,000. Finally, Integral Health Asset Management LLC increased its position in shares of Keros Therapeutics by 112.5% during the 2nd quarter. Integral Health Asset Management LLC now owns 85,000 shares of the company’s stock valued at $3,884,000 after purchasing an additional 45,000 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.